Year: 2025
Type: article
Study design: Case Report
Abstract: Bortezomib is a targeted anti - cancer medication used primarily to treat Multiple Myeloma and Mantle Cell Lymphoma in adults. It is classified as a Protease Inhibitor, which works by reversibly inhibiting the protein complex responsible for degrading damaged proteins within cells.[1] We report the case of a patient with Multiple Myeloma who developed Paralytic Ileus while on Bortezomib.
Authors: Rimal Roy, Sara Kodiattu, Rency Abraham, Jacob R S
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4413380741